News | September 19, 2014

Highest Level Evidence Published in Neurosurgery Journal Indicates Better Outcomes When Using iMRI

Interim analysis of triple-blind, parallel-controlled trial proves intraoperative MRI more effective than conventional neurosurgery for certain brain tumors

Imris Visius iMRI

The Imris Visius iMRI at Huashan Hospital in Shanghai, China, provides neurosurgeons high-quality MR images during surgery which results in more complete brain tumor removal in patients. (CNW Group/Imris Inc.)

September 19, 2014 — Imris Inc. announced that a recently published article in the journal Neurosurgery is the highest-level clinical evidence to show that the use of Visius intraoperative magnetic resonance imaging (iMRI) in brain tumor surgery results in complete tumor removal in more patients with glioma tumors.

Led by Dr. Jin-song Wu, the neurosurgical team at Huashan Hospital at Fudan University in Shanghai, China, conducted the study and wrote the interim analysis article that was published in August. Wu and the clinical team were honored with the Journal of Neuro-Oncology Award at the Congress of Neurological Surgeons (CNS) Annual Meeting in October 2013 for their study design and abstract.

The prospective, parallel, randomized, triple-blind controlled trial design provides the most objective data and therefore highest level evidence to date of the value of iMRI in treating both low and high-grade gliomas. The early results reinforce that high-field iMRI-guided surgery is more effective in achieving complete resection than conventional neuronavigation-guided surgery. Other published studies on high-field iMRI have been mainly retrospective.

"iMRI is a practical and valuable asset to increasing the extent of resection for cerebral gliomas, with a specific significant influence for low grade gliomas," Wu said. "With trends to statistical significance, these early results are the highest level of iMRI evidence for glioma surgery now available. This leads to more improved overall survivability and quality of life than using conventional neuronavigation."

The low-grade glioma (LGG) subgroup patients who were treated in a Visius Surgical Theatre using iMRI had a statistically significant complete resection rate of 82 percent compared to 43 percent for the control group of conventional surgery patients. For the high-grade glioma (HGG) patients, 91 percent of those treated with iMRI had complete resection compared to 73 percent for the control group. These results are confirmed by volumetric analysis. The LGG subgroup met the endpoint early and that arm of the study stopped enrolling additional patients. The study continues for HGG patients.

The Imris Visius Surgical Theatre with iMRI at Huashan Hospital provides neurosurgeons high-quality MR images during surgery to see the area of the brain they are operating on in exquisite detail, see tumor size and shape, and distinguish between healthy and unhealthy tissue more easily. The surgeon can take images before completing the surgery and check if additional tumor or abnormal tissue removal is needed to reduce risk of re-operation.

Unlike other iMRI systems, the Imris scanner moves between two adjoining rooms - one intended for surgery and the other for diagnostic scanning - on ceiling-mounted rails to the patient so the surgical team can maintain optimal surgical positioning, access and techniques without moving the patient.

One of five Visius Surgical Theatre installations in China, more than 1,000 patient procedures have been completed using the Fudan University iMRI since its installation in Sept. 2010.

For more information: journals.lww.com/neurosurgery/Citation/2014/08001/3_0_T_Intraoperative_Magnetic_Resonance.31.aspx.

Related Content

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...
Carotid Artery MRI Improves Cardiovascular Disease Risk Assessment
News | Magnetic Resonance Imaging (MRI) | October 23, 2018
Magnetic resonance imaging (MRI) measurements of wall thickness in the carotid arteries improve cardiovascular disease...
The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

Feature | ASTRO | October 20, 2018 | By Greg Freiherr
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S.